GeneSight, a Mason-based company specializing in mental health medication, expanded its wellness services in the community.

With a simple cheek swab, the GeneSight test generates a report that gives healthcare providers insight into how a patient may metabolize or respond to certain psychiatric medications.

UnitedHealth (UNH) on Friday disclosed that it would stop covering multi-panel pharmacogenetic tests, including Myriad’s (MYGN) GeneSight, effective January 1, 2025, in a number of plans ...

A significant reason for the Hold rating is the recent decision by UnitedHealthcare (UNH) to alter its coverage of GeneSight, a key product for Myriad. This change is seen as a potential headwind ...

Myriad Genetics said it is in talks with UnitedHealthcare to ensure that enrollees continue to have access to its GeneSight mental health medication test after the insurer changed its coverage policy.

Piper Sandler thinks Myriad Genetics (MYGN), which has seen its shares fall nearly 22% on Friday morning, is trading down on a coverage decision on GeneSight by UnitedHealth (UNH), which will take ...

After initial review of the updated policy, the company strongly disagrees with UnitedHealthcare’s inclusion of GeneSight in its decision to change its coverage policy of multi-gene panels based ...

The company reported a 34% year-over-year increase in GeneSight revenues, with volume growth of 10% and improved revenue per test. Myriad Genetics Inc (NASDAQ:MYGN) continues to see positive ...